A SINGLE-BLIND, RANDOMIZED HOME-USE STUDY, IN 50 HEALTHY FEMALES (ALL WITH SELF-ASSESSED OR DIAGNOSED MENOPAUSE OR PERIMENOPAUSE), TO EVALUATE THE EFFICACY OF AN ACTIVE SUPPLEMENT IN TREATING HOT FLASHES AND NIGHT SWEATS WHEN COMPARED TO A PLACEBO, MEASURED BY SELF-PERCEPTION QUESTIONNAIRES (SPQ)

Prepared for:

Nutreance 401 Riversville Rd. Greenwich CT, 06831 USA Prepared by:

Princeton Consumer Research Corp. Baypoint Commerce Center 9600 Koger Blvd N., Suite 120, St Petersburg Florida, 33702

Draft Report Version 1: 21st November 2023 Draft Report Version 2: 28th November 2023 Final Report v1: 8th December 2023 Final Report v2: 12th December 2023 Final Report v3: 8th January 2024

A SINGLE-BLIND, RANDOMIZED HOME-USE STUDY, IN 50 HEALTHY FEMALES (ALL WITH SELF-ASSESSED OR DIAGNOSED MENOPAUSE OR PERIMENOPAUSE), TO EVALUATE THE EFFICACY OF AN ACTIVE SUPPLEMENT IN TREATING HOT FLASHES AND NIGHT SWEATS WHEN COMPARED TO A PLACEBO, MEASURED BY SELF-PERCEPTION QUESTIONNAIRES (SPQ)

Princeton Consumer Research Report No: NUTUSE10F

I declare that the following report constitutes a true and faithful account of the procedures adopted and the results obtained in the performance of this study. The aspects of the study conducted by PCR Corp were performed, where relevant, in accordance with the principles of Good Clinical Research Practice.

Barrie Drewitt (Principal Investigator)

BDrewitt

12 / 01 / 2024 Date.....

K. Edwards

Khari Edwards (Project Manager)

> 11 / 01 / 2024 Date.....

QUALITY ASSURANCE STATEMENT:

This report has been audited and is considered to be an accurate description of the methods used and an accurate presentation of the data obtained during the conduct of the study.

Anne M. Campbell, BS (Quality Assurance Auditor) Anne M. Campbell

.....

11 / 01 / 2024 Date.....

Final Report v3

Page 2 of 21

TABLE OF CONTENTS

1.	SUMMARY	4
2.	KEY STUDY PERSONNEL AND RESPONSIBILITIES	6
3.	OBJECTIVE	7
4.	STUDY DESIGN	7
5.	SELECTION OF SUBJECTS	7
6.	METHOD	8
7.	STUDY ETHICS	. 10
8.	QUALITY ASSURANCE	. 10
9.	STUDY DATA	. 10
10.	STATISTICAL ANALYSIS RESULTS	12
11.	CONCLUSIONS	15

APPENDICES

APPENDIX 1: FINAL STUDY PROTOCOL

APPENDIX 2: DEMOGRAPHICS

APPENDIX 3: SELF-PERCEPTION QUESTIONNAIRES (SPQS)

APPENDIX 4: RECORD RETENTION AND ADVERTISING STATEMENT

1.	SUMMARY							
	Title:	A Single-Blind, Randomized Home-Use Study, in 50 Healthy Females (All with Self-Assessed or Diagnosed Menopause or Perimenopause), To Evaluate the Efficacy of An Active Supplement in Treating Hot Flashes and Night Sweats When Compared to A Placebo, Measured by Self- Perception Questionnaires (SPQ).						
	Study Design:	Single-blind, randomized, placebo-controlled home-use study.						
	Test Article:	 Nutreance Menovair Menopause Supplement Placebo (empty gelatin capsules) 						
	Study Duration:	30 days						
	Number of Subjects:	Fifty-five (55) subjects were enrolled onto the study so that fifty subjects (50) subjects could be expected to complete the study. All fifty-five subjects completed the study.						
	Type of Subjects:	Healthy female volunteers, aged 40 and over with self- assessed symptoms of Menopause or Perimenopause (experiencing hot flashes, mood swings, night sweats).						
	Method:	Subjects attended the testing facility (Baseline) where Informed Consent and eligibility were verified. Once accepted, subjects were randomized to treatment (active or placebo dietary supplement, instructed on how to take the supplement. Subjects were issued the product per the randomization, to use for 30 days. Subjects were provided with a daily diary to record daily usage and any adverse reactions.						
		Subjects returned to the testing facility after 30 days of test article use to complete the final study questionnaire. The diaries were reviewed for compliance and the test products were collected.						
	Study Dates:	Study Start Date: 27 th September 2023 Study End Date: 26 th October 2023						
	Location:	Princeton Consumer Research Corp. Baypoint Commerce Center 9600 Koger Blvd N., Suite 120 St Petersburg, Florida 33702						

Conclusion:

Subjects completed a Self-Perception Questionnaires (SPQ) after 30 days of the assigned test product use. Subjects were asked how strongly they agreed or disagreed to each of the SPQ statements using a 5-Point Likert Scale. The frequency of responses was summarized for each question.

Within-treatment analyses was performed using top box analysis for all questions for both the Active Test Product Treatment group and the Placebo Test Product Treatment group. The statements that had statistically significant positive responses for the Active Test Group are presented alongside the responses for each statement for the Placebo Test Group shown in the summary table below.

As shown below the Active Test Group had statistically significant positive Top Box results (Agree and Strongly Agree) to the questions listed below while the Placebo Test Group had no statistically significant positive responses to the same questions.

Questions	Act	live	Plac	ebo
QUESTIONS	%	р	%	р
1. Did you notice a reduction in the intensity of hot flashes?	69.70%	0.04*	31.82%	0.13
2. Did you notice a reduction in the frequency of night sweats?	72.73%	0.01*	31.82%	0.13
5. Did you notice a reduction in the intensity of night sweats?	69.70%	0.04*	36.36%	0.29
6. Did you notice a reduction in the frequency of night sweats?	75.76%	<0.01*	31.82%	0.13
16. Did you experience fewer sleep interruptions throughout the night?	72.73%	0.01*	31.82%	0.13
18. Would you recommend the product?	72.73%	0.01*	31.82%	0.13
19. Were you satisfied with the product?	75.76%	<0.01*	36.36%	0.29

2. <u>KEY STUDY PERSONNEL AND RESPONSIBILITIES</u>

Key personnel	General responsibilities
Principal Investigator (PI)	
Barrie Drewitt	The Principal Investigator (PI) was
PCR Corp	responsible for ensuring sufficient resources
Baypoint Commerce Center	were available to conduct the study and
9600 Koger Blvd N., Suite 120	was responsible for the study design, review
St. Petersburg	of the study protocol and report and
Florida, 33702	ensuring that they concurred with the study
	design and findings reported.
Tel: +1 (727) 576-7300	
Project Manager (PM)	
Khari Edwards	The Project Manager (PM) was involved with
PCR Corp	the study design, compiling the results, and
8 Richmond Road	writing the clinical report.
Dukes Park	
Chelmsford	
Essex	
CM2 6UA	
United Kingdom	
Tel: 01245 934050	
Project Supervisor (PS)	
Ashley Ogurek	The Project Supervisor (PS) was responsible
PCR Corp	for the conduct of the study on a daily basis.
Baypoint Commerce Center	
9600 Koger Blvd N., Suite 120	
St. Petersburg	
Florida, 33702	
Tel: +1 (727) 576-7300	
Project Co-ordinator (PC)	
Dan Watters	The PC was the primary point of contact on
Nutreance	behalf of the Sponsor of this project and
401 Riversville Rd.	represented the Sponsor of this study.
Greenwich	
CT. 06831	
USA	
Email: dwatters29@gmail.com	

3. OBJECTIVE

The objective of this study was to evaluate the performance of 1 Test Article (Dietary Supplement) by peri and post-menopausal women who experience menopausal symptoms. The supplement was taken at home daily. Efficacy was measured by self-perception questionnaire (SPQ) over a 30-day period. The supplement is designed to help relieve symptoms associated with menopause such as hot flashes, mood swings and night sweats.

Please note that it is the responsibility of the sponsor to determine the testing and study designs required for submission to entities such as the Home Shopping Network, QVC, etc.

4. STUDY DESIGN

Single-blind, randomized, placebo-controlled home-use study assessed by selfperception questionnaires.

5. <u>SELECTION OF SUBJECTS</u>

5.1 SCREENING

Subjects were screened over the telephone to allow for a sufficient number of subjects to be enrolled and issued the products to use for 30 days, so that approximately 50 subjects would be expected to complete the study. Subjects satisfied the following inclusion and exclusion criteria and were prepared to accept the prohibitions and restrictions.

The suitability of potential subjects was confirmed before their acceptance by telephone interview.

5.2 INCLUSION CRITERIA

- 1. Healthy female volunteers aged 40 and over of any ethnicity or skin type who are peri-or post-menopausal.
- 2. Subject has self-assessed symptoms of Menopause or Perimenopause (e.g., is currently experiencing hot flashes, mood swings, and/or night sweats).
- 3. Subject is not pregnant, trying for pregnancy or breastfeeding.
- 4. Subjects is taking birth control medication allowed as long as the prescription has not been changed in the last 6 months prior to the start of the study.
- 5. Individuals with no known medical conditions that, in the investigator's opinion, may interfere with study participation.
- 6. Willingness to cooperate and participate by following the study requirements.
- 7. Individuals must sign informed consent and confidentiality agreement.

5.3 EXCLUSION CRITERIA

- 1. Subject is pregnant, nursing, or planning to become pregnant.
- 2. Individuals that are being treated for cancer, or breast cancer. Also subjects that have any hormone-sensitive conditions such as, endometriosis, or uterine fibroids or a condition that might be made worse by exposure to estrogen.

- 3. Individuals currently taking certain medications which in the opinion of the Investigator, may interfere with the study. This would include but not be limited to routine high dosage use of anti-inflammatory drugs (aspirin, ibuprofen, corticosteroids) immunosuppressive drugs or antihistamine medications (steroid nose drops and/or eye drops are permitted), and insulin, anti-hypertensive drugs, antibiotics or OTC or prescription medications for Menopause or Menopausal Symptoms. Additionally subjects currently taking blood thinning medications.
- 4. Individuals with uncontrolled metabolic diseases such as diabetes (Type I and II), hypertension, hyperthyroidism or hypothyroidism, severe chronic asthma, immunological disorders such as HIV positive, AIDS and systemic lupus erythematosus or mastectomy for cancer involving removal of lymph nodes.
- 5. Known sensitivity/allergy to the test article, similar materials or their constituents.
- 6. Current participation in a similar dietary supplement study or with exclusionary requirements that would interfere with this study.

5.4 PROHIBITIONS AND RESTRICTIONS

- 1. Subject agrees to use the designated test article taking two (2) capsules daily during the 30-day period and to use the test article per the usage instructions provided.
- 2. Subject agrees not start a prescription medication course at any point during the course of the study unless approved by the Principal Investigator.
- 3. Subject becomes pregnant.
- 4. Subjects must attend both visits and complete the SPQ.
- 5. Subject must fill out the usage diary daily and return products at the end of the study.

6. <u>METHOD</u>

6.1 TEST ARTICLES

Test Articles were supplied by the Sponsor in identical commercial packaging for blinding purposes. The subjects were assigned the test products according to the randomization scheme shown below:

Subjects were assigned a test article according to the following randomization:

Subject #	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Test Article	2	1	2	1	2	1	1	1	2	2	2	2	1	1	1
Subject #	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30
Test Article	2	1	2	1	2	1	1	1	1	1	1	1	1	2	1
Subject #	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45
Test Article	1	2	2	2	2	1	1	1	2	1	2	1	1	1	1
Subject #	46	47	48	49	50	51	52	53	54	55					
Test Article	2	2	2	1	1	2	1	1	2	1					

The Sponsor provided the ingredient listing the test articles and certified that the products supplied to PCR Corp for the clinical trial had been manufactured/formulated with ingredients that are safe and suitable for the product's stated purpose.

Test articles were supplied to the subjects at baseline along with directions for usage. Subjects were instructed to take the capsules twice daily at home over a 30-day period according to the following usage instructions:

<u>Usage</u>

For daily use: Take two (2) capsules with water every morning before having a meal.

DO NOT CONSUME ALCOHOL UNTIL YOU ARE FAMILIAR WITH THE TEST ARTICLE EFFECTS. AVOID EXCESSIVE CONSUMPTION OF ALCOHOL. KEEP OUT OF THE REACH OF CHILDREN. DO NOT EXCEED THE RECOMMENDED DOSE.

6.2 STUDY PROCEDURES AND EVALUATIONS

Visit 1 - Study Day 1 (Baseline)

Subjects attended the study facility where informed consent were collected, and eligibility was verified. Once accepted, subjects were issued the test article according to the randomization, along with instructions and a diary to record product usage.

The number of test article capsules were recorded by study staff before product was issued. Approximately thirty (30) subjects were assigned the active test article and approximately twenty (20) subjects were issued the placebo test article 2. Subjects were provided with enough test article to use for the entire 30 days.

Subjects were given a return time for their next visit and were asked to return with their daily diary and test article.

Visit 2 - Study Day 30 (± 1 Day)

Subjects returned to the testing facility after 30 days of product use for their final visit. Subjects brought their remaining test article and usage diary for review. Products were counted and compliance with the usage instructions was assessed, and diaries were also verified for compliance. Subjects were asked if they had experienced any adverse effects related to test article usage or changes to their health. Subjects completed a Self-perception Questionnaire (SPQ).

When completed subjects received compensation and their participation was considered complete.

7. STUDY ETHICS

Declaration of Helsinki and ICH Good Clinical Practices

The study conformed to the requirements of the 1964 Declaration of Helsinki and its subsequent amendments (World Medical Association; 2013). The study was conducted in accordance with applicable International Council for Harmonization. 2016. Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2) in as much as they apply to consumer product testing.

Subject Consent

Subjects were informed of the nature, purpose and known risk of the study both orally and in writing and gave their written informed consent before participating in the study (Appendix 1). Subjects were advised that they were free to withdraw from the study at any time without being obliged to give a reason. They were compensated for their time and inconvenience.

Indemnity Provision

The Sponsor was responsible, without regard to legal liability, and indemnified PCR Corp., or any of their respective officers or employees in the event of claims for compensation from subjects suffering injury arising out of the administration or use of the test articles, or of any procedure that was required under the protocol as a result of a subject participation in this study, except and insofar as such claims arise as a result of any negligent act or omission on the part of PCR Corp. employees or any persons undertaking or involved in the study by arrangement with PCR Corp.

8. QUALITY ASSURANCE

An audit of the final report was completed, for accuracy and completeness of presentation. Additionally, the study may have been subject to the following Quality Assurance procedures:

- Review of protocol and protocol amendments for completeness, clarity and adequacy.
- Inspection and/or audit of critical phases of study conduct for compliance with protocol and Princeton Clinical Research procedures.

The Princeton Clinical Research Corp. Quality Assurance Manager will inform Princeton Clinical Research Corp. management of any findings that may affect the integrity of the study.

9. STUDY DATA

9.1 LOCATION AND DATES OF THE STUDY

The study was performed at PCR Corp. located in St. Petersburg, Florida. The study started on 27th September 2023 and completed on 26th October 2023.

9.2 SUBJECTS

Fifty-five (55) subjects were screened and enrolled onto the study, and all fifty-five (55) subjects completed the study. Thirty-three (33) subjects were assigned use of the active supplement, and twenty-two (22) subjects were assigned use of the placebo.

A summary of subject demographics is in the table below. A complete listing of subject demographics can be found in Appendix 2.

All Su	bjects
Age	
Count	55
Mean	57.87
Std	8.64
Median	60
Range	41 - 76
Gender	
Female	55 (100.0 %)
Race	
White	27 (49.09 %)
Black	27 (49.09 %)
Asian	1 (1.82 %)
Ethnicity	
Non-Hispanic/Latino	53 (96.36 %)
Hispanic	2 (3.64 %)
Menopausal State	
Post	47 (85.45 %)
Peri	8 (14.55 %)
Test Article	
Supplement	33 (60.0 %)
Placebo	22 (40.0 %)

Active Su	oplement	Placebo					
Age		Age					
Count	33	Count	22				
Mean	59.55	Mean	55.36				
Std	8.73	Std	8.06				
Median	61	Median	56.5				
Range	41 - 76	Range	43 - 68				
Gender		Gender					
Female	33 (100.0 %)	Female	22 (100.0 %)				
Race		Race					
White	18 (54.55 %)	Black	12 (54.55 %)				
Black	15 (45.45 %)	White	9 (40.91 %)				
Ethnicity		Asian	1 (4.55 %)				
Non-Hispanic/Latino	32 (96.97 %)	Ethnicity					
Hispanic	1 (3.03 %)	Non-Hispanic/Latino	21 (95.45 %)				
Menopausal State		Hispanic	1 (4.55 %)				
Post	29 (87.88 %)	Menopausal State					
Peri	4 (12.12 %)	Post	18 (81.82 %)				
		Peri	4 (18.18 %)				

Page 11 of 21

9.3 PROTOCOL DEVIATIONS

The protocol was followed except for one minor deviation. Subject 41 failed to return one test article container at the final visit. In the opinion of the Investigator, this deviation did not affect the integrity of the study.

9.4 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS

No adverse reactions were documented during the course of this study.

10. STATISTICAL ANALYSIS RESULTS

Data tables of individual results are included in Appendix 3.

1) Demographics:

A. Descriptive statistics (age, gender, race, ethnicity, menopausal state)

Self-Perception Questionnaire responses (5-point Likert scale) at 30 days of test article usage. The percentage of responses to each SPQ question was calculated and the percentage of the top 2 positive responses (Strongly Agree and Agree) were reported.


The frequency of responses was summarized for each question. Within-treatment analyses was performed using top box analysis.

All statistical tests of hypothesis employed a level of significance of 0.05 and no adjustments were made for the number of tests performed.

10.1 SELF-PERCEPTION QUESTIONNAIRES – SUPPLEMENT DAY 30

		Not T	op Box	To		
Questions	Total	N	%	N	%	p-value
1. Did you notice a reduction in the intensity of hot flashes?	33	10	30.30%	23	69.70%	0.04*
2. Did you notice a reduction in the frequency of hot flashes?	33	9	27.27%	24	72.73%	0.01*
3. Do you feel less vulnerable to hot flashes?	33	12	36.36%	21	63.64%	0.16
4. Did you notice feeling less sensitive to temperature changes?	33	15	45.45%	18	54.55%	0.73
5. Did you notice a reduction in the intensity of night sweats?	33	10	30.30%	23	69.70%	0.04*
6. Did you notice a reduction in the frequency of night sweats?	33	8	24.24%	25	75.76%	<0.01*
7. Are you less worried about night sweats interrupting your sleep?	33	13	39.39%	20	60.61%	0.30
8. Did you notice less frequent mood swings?	33	13	39.39%	20	60.61%	0.30
9. Did you notice your mood was more stable?	33	12	36.36%	21	63.64%	0.16
10. Did you notice feeling less irritable?	33	14	42.42%	19	57.58%	0.49
11. Did you notice an improvement in your overall mood?	33	11	33.33%	22	66.67%	0.08
12. Did you notice any weight loss or your clothes fitting better?	33	27	81.82%	6	18.18%	<0.01*
13. Did you notice an improvement in your energy level?	33	15	45.45%	18	54.55%	0.73
14. Did you notice less fatigue?	33	12	36.36%	21	63.64%	0.16
15. Did you notice an improvement in sleep quality?	33	11	33.33%	22	66.67%	0.08
16. Did you experience fewer sleep interruptions throughout the night?	33	9	27.27%	24	72.73%	0.01*
17. Did you notice an improvement in hair volume?	33	24	72.73%	9	27.27%	0.01*
18. Would you recommend the product?	33	9	27.27%	24	72.73%	0.01*
19. Were you satisfied with the product?	33	8	24.24%	25	75.76%	<0.01*

Significant if p-value < 0.05; Please note that in some cases Not Top Box was statistically significant.



SPQ - SUPPLEMENT


Final Report v3

Page 13 of 21

SELF-PERCEPTION QUESTIONNAIRES – PLACEBO DAY 30 10.2

		Not T	op Box	Тор	p-	
Questions	Total	Ν	%	N	%	value
1. Did you notice a reduction in the intensity of hot flashes?	22	15	68.18%	7	31.82%	0.13
2. Did you notice a reduction in the frequency of hot flashes?	22	15	68.18%	7	31.82%	0.13
3. Do you feel less vulnerable to hot flashes?	22	15	68.18%	7	31.82%	0.13
4. Did you notice feeling less sensitive to temperature changes?	22	15	68.18%	7	31.82%	0.13
5. Did you notice a reduction in the intensity of night sweats?	22	14	63.64%	8	36.36%	0.29
6. Did you notice a reduction in the frequency of night sweats?	22	15	68.18%	7	31.82%	0.13
7. Are you less worried about night sweats interrupting your sleep?	22	14	63.64%	8	36.36%	0.29
8. Did you notice less frequent mood swings?	22	16	72.73%	6	27.27%	0.05*
9. Did you notice your mood was more stable?	22	17	77.27%	5	22.73%	0.02*
10. Did you notice feeling less irritable?	22	16	72.73%	6	27.27%	0.05*
11. Did you notice an improvement in your overall mood?	22	16	72.73%	6	27.27%	0.05*
12. Did you notice any weight loss or your clothes fitting better?	22	18	81.82%	4	18.18%	<0.01*
13. Did you notice an improvement in your energy level?	22	15	68.18%	7	31.82%	0.13
14. Did you notice less fatigue?	22	16	72.73%	6	27.27%	0.05*
15. Did you notice an improvement in sleep quality?	22	15	68.18%	7	31.82%	0.13
16. Did you experience fewer sleep interruptions throughout the night?	22	15	68.18%	7	31.82%	0.13
17. Did you notice an improvement in hair volume?	22	18	81.82%	4	18.18%	<0.01*
18. Would you recommend the product?	22	15	68.18%	7	31.82%	0.13
19. Were you satisfied with the product?	22	14	63.64%	8	36.36%	0.29

Significant if p-value < 0.05; Please note, all statistically significant responses were for Not Top Box.



SPQ - PLACEBO

Final Report v3

Page 14 of 21

11. CONCLUSIONS

Subjects completed a Self-Perception Questionnaires (SPQ) after 30 days of the assigned test product use. Subjects were asked how strongly they agreed or disagreed to each of the SPQ statements using a 5-Point Likert Scale. The frequency of responses was summarized for each question.

Within-treatment analyses was performed using top box analysis for all questions for both the Active Test Product Treatment group and the Placebo Test Product Treatment group. The statements that had statistically significant positive responses for the Active Test Group are presented alongside the responses for each statement for the Placebo Test Group shown in the summary table below.

As shown below the Active Test Group had statistically significant positive Top Box results (Agree and Strongly Agree) to the questions listed below while the Placebo Test Group had no statistically significant positive responses to the same questions.

Questions	Act	live	Plac	ebo
QUESTIONS	%	р	%	р
1. Did you notice a reduction in the intensity of hot flashes?	69.70%	0.04*	31.82%	0.13
2. Did you notice a reduction in the frequency of night sweats?	72.73%	0.01*	31.82%	0.13
5. Did you notice a reduction in the intensity of night sweats?	69.70%	0.04*	36.36%	0.29
6. Did you notice a reduction in the frequency of night sweats?	75.76%	<0.01*	31.82%	0.13
16. Did you experience fewer sleep interruptions throughout the night?	72.73%	0.01*	31.82%	0.13
18. Would you recommend the product?	72.73%	0.01*	31.82%	0.13
19. Were you satisfied with the product?	75.76%	<0.01*	36.36%	0.29

No subjects reported any adverse events or reactions while participating on the study.

Final Report v3

2.1 DEMOGRAPHICS

Subject/					Date of Last		
Rando #	Age	Gender	Race	Ethnicity	Menstrual Cycle	Menopausal State	Test Article
01	<u> </u>	Female	White	Hispanic	May-14	Post	Placebo
02	55	Female	White	Non-Hispanic/Latino	Mar-18	Post	Supplement
03	58	Female	Black	Non-Hispanic/Latino	Mar-12	Post	Placebo
04	49	Female	Black	Non-Hispanic/Latino	Mar-23	Peri	Supplement
05	43	Female	Black	Non-Hispanic/Latino	Unk-10	Post	Placebo
06	70	Female	White	Non-Hispanic/Latino	Dec-09	Post	Supplement
07	69	Female	White	Non-Hispanic/Latino	Unk-13	Post	Supplement
08	64	Female	Black	Non-Hispanic/Latino	Sep-03	Post	Supplement
09	66	Female	Black	Non-Hispanic/Latino	Mar-08	Post	Placebo
10	47	Female	Asian	Non-Hispanic/Latino	Mar-21	Post	Placebo
11	68	Female	White	Non-Hispanic/Latino	Unk-02	Post	Placebo
12	43	Female	White	Non-Hispanic/Latino	Sep-23	Peri	Placebo
13	51	Female	White	Non-Hispanic/Latino	Jul-15	Post	Supplement
14	41	Female	Black	Non-Hispanic/Latino	Sep-23	Peri	Supplement
15	69	Female	Black	Non-Hispanic/Latino	Unk-13	Post	Supplement
16	45	Female	White	Non-Hispanic/Latino	Jan-15	Post	Placebo
17	53	Female	White	Non-Hispanic/Latino	Dec-13	Post	Supplement
17	60	Female	Black	Non-Hispanic/Latino	Nov-98	Post	Placebo
10	57	Female	White	Non-Hispanic/Latino	Sep-19	Post	Supplement
20	60	Female	Black	Non-Hispanic/Latino	Jun-07	Post	
20	52	Female	White	Non-Hispanic/Latino	Unk-17	Post	Placebo Supplement
21	76			-	Jul-77		Supplement
22	54	Female	White	Non-Hispanic/Latino	Jun-23	Post Peri	
23 24	65	Female	Black	Non-Hispanic/Latino		Post	Supplement
		Female	Black	Non-Hispanic/Latino	Dec-07		Supplement
25 26	51	Female	Black	Non-Hispanic/Latino	Unk-18	Post	Supplement
	68	Female	Black	Non-Hispanic/Latino	Aug-18	Post	Supplement
27	64	Female	White	Non-Hispanic/Latino	Dec-14	Post	Supplement
28	57	Female	Black	Non-Hispanic/Latino	Unk-06	Post	Supplement
29	60	Female	White	Non-Hispanic/Latino	Dec-18	Post	Placebo
30	65	Female	Black	Non-Hispanic/Latino	Mar-19	Post	Supplement
31	68	Female	White	Non-Hispanic/Latino	May-96	Post	Supplement
32	49	Female	Black	Non-Hispanic/Latino	Sep-23	Peri	Placebo
33	55	Female	Black	Non-Hispanic/Latino	Jun-22	Post	Placebo
34	63	Female	Black	Non-Hispanic/Latino	Aug-13	Post	Placebo
35	55	Female	Black	Non-Hispanic/Latino	Unk-19	Post	Placebo
36	53	Female	White	Non-Hispanic/Latino	Sep-17	Post	Supplement
37	50	Female	White	Non-Hispanic/Latino	Unk-95	Post	Supplement
38	48	Female	White	Non-Hispanic/Latino	Unk-15	Post	Supplement
39	64	Female	White	Non-Hispanic/Latino	Apr-08	Post	Placebo
40	63	Female	Black	Non-Hispanic/Latino	Unk-08	Post	Supplement
41	46	Female	White	Non-Hispanic/Latino	Sep-23	Peri	Placebo
42	66	Female	White	Hispanic	Unk-19	Post	Supplement
43	72	Female	White	Non-Hispanic/Latino	Feb-99	Post	Supplement
44	66	Female	White	Non-Hispanic/Latino	Feb-06	Post	Supplement
45	60	Female	Black	Non-Hispanic/Latino	Feb-10	Post	Supplement
46	44	Female	Black	Non-Hispanic/Latino	Aug-23	Peri	Placebo
47	65	Female	White	Non-Hispanic/Latino	Feb-12	Post	Placebo
48	55	Female	Black	Non-Hispanic/Latino	Mar-21	Post	Placebo
49	61	Female	Black	Non-Hispanic/Latino	Dec-00	Post	Supplement
50	63	Female	Black	Non-Hispanic/Latino	Dec-10	Post	Supplement
51	52	Female	Black	Non-Hispanic/Latino	Aug-18	Post	Placebo
52	42	Female	White	Non-Hispanic/Latino	Aug-23	Peri	Supplement
53	65	Female	White	Non-Hispanic/Latino	Dec-16	Post	Supplement
54	60	Female	White	Non-Hispanic/Latino	Jun-13	Post	Placebo
55	58	Female	Black	Non-Hispanic/Latino	Mar-06	Post	Supplement

Supplement Count = 33 | Placebo Count = 22

3.1 SELF-PERCEPTION QUESTIONNAIRE – Active Supplement

Subject Number	notice a reduction in the intensity	2. Did you notice a reduction in the frequency of hot flashes?	3. Do you feel less vulnerabl e to hot flashes?	4. Did you notice feeling less sensitive to temperat ure changes?	5. Did you notice a reduction in the intensity of night sweats?	6. Did you notice a reduction in the frequency of night sweats?	7. Are you less worried about night sweats interrupting your sleep?	8. Did you notice less frequent mood swings?	9. Did you notice your mood was more stable?	10. Did you notice feeling less irritable?	11. Did you notice an improvem ent in your overall mood?	12. Did you notice any weight loss or your clothes fitting better?	13. Did you notice an improvem ent in your energy level?	14. Did you notice less fatigue?	15. Did you notice an improvem ent in sleep quality?	16. Did you experience fewer sleep interruptions throughout the night?	17. Did you notice an improvem ent in hair volume?	18. Would you recomme nd the product?	19. Were you satisfied with the product?
2	Agree	Strongly Agree	Agree	Agree	Strongly Agree	Strongly Agree	Agree	Strongly Agree	Strongly Agree	Neither Agree Nor Disagree	Agree	Neither Agree Nor Disagree	Agree	Agree	Strongly Agree	Strongly Agree	Agree	Strongly Agree	Strongly Agree
4	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Agree	Neither Agree Nor Disagree	Agree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Agree	Agree	Neither Agree Nor Disagree	Agree	Disagree	Disagree	Neither Agree Nor Disagree	Agree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Agree	Neither Agree Nor Disagree
6	Agree	Agree	Neither Agree Nor Disagree	Agree	Agree	Agree	Agree	Agree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Agree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Agree
7	Agree	Agree	Strongly Agree	Agree	Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Disagree	Neither Agree Nor Disagree	Agree	Agree	Strongly Agree	Neither Agree Nor Disagree	Strongly Agree	Strongly Agree
8	Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Agree	Agree	Agree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Strongly Disagree	Disagree	Agree	Agree	Agree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree
13	Agree	Agree	Neither Agree Nor Disagree	Agree	Agree	Agree	Agree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Disagree	Agree	Agree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Agree	Agree
14	Agree	Agree	Agree	Agree	Agree	Strongly Agree	Neither Agree Nor Disagree	Agree	Agree	Agree	Agree	Neither Agree Nor Disagree	Agree	Agree	Agree	Agree	Neither Agree Nor Disagree	Agree	Agree
15	Agree	Agree	Neither Agree Nor Disagree	Agree	Agree	Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Neither Agree Nor Disagree	Agree	Agree	Agree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Strongly Agree	Strongly Agree
17	Agree	Agree	Agree	Neither Agree Nor Disagree	Disagree	Disagree	Disagree	Neither Agree Nor Disagree	Agree	Agree	Agree	Agree	Neither Agree Nor Disagree	Agree	Agree	Agree	Agree	Agree	Agree
19	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Neither Agree Nor Disagree	Agree	Agree	Agree	Agree	Neither Agree Nor Disagree	Agree	Agree
21	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree
22	Agree	Agree	Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Neither Agree Nor Disagree	Agree	Agree	Agree	Agree	Neither Agree Nor Disagree	Strongly Agree	Strongly Agree
23	Agree	Strongly Agree	Agree	Agree	Strongly Agree	Strongly Agree	Agree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Agree	Neither Agree Nor Disagree	Agree	Agree	Agree	Agree	Neither Agree Nor Disagree	Agree	Strongly Agree
24	Strongly Agree	Agree	Agree	Agree	Strongly Agree	Agree	Strongly Agree	Disagree	Neither Agree Nor Disagree	Agree	Neither Agree Nor Disagree	Disagree	Neither Agree Nor Disagree	Strongly Agree	Neither Agree Nor Disagree	Agree	Neither Agree Nor Disagree	Strongly Agree	Strongly Agree
25	Agree	Agree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Agree	Agree	Neither Agree Nor Disagree	Agree	Agree	Agree	Agree	Neither Agree Nor Disagree	Agree	Neither Agree Nor Disagree	Agree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Agree	Agree
26	Agree	Agree	Strongly Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Strongly Agree	Neither Agree Nor Disagree	Agree	Agree	Agree	Agree	Agree	Agree	Strongly Agree

Final Report v3

Page 18 of 21

PRINCETON CONSUMER RESEARCH CORP. REPORT: NUTUSE10F APPENDIX 3: SELF-PERCEPTION QUESTIONNAIRES (SPQs)

Subject Number	1. Did you notice a reduction in the intensity of hot flashes?	2. Did you notice a reduction in the frequency of hot flashes?	3. Do you feel less vulnerabl e to hot flashes?	4. Did you notice feeling less sensitive to temperat ure changes?	5. Did you notice a reduction in the intensity of night sweats?	6. Did you notice a reduction in the frequency of night sweats?	7. Are you less worried about night sweats interrupting your sleep?	8. Did you notice less frequent mood swings?	9. Did you notice your mood was more stable?	10. Did you notice feeling less irritable?	11. Did you notice an improvem ent in your overall mood?	12. Did you notice any weight loss or your clothes fitting better?	13. Did you notice an improvem ent in your energy level?	14. Did you notice less fatigue?	15. Did you notice an improvem ent in sleep quality?	16. Did you experience fewer sleep interruptions throughout the night?	17. Did you notice an improvem ent in hair volume?	18. Would you recomme nd the product?	19. Were you satisfied with the product?
27	Disagree	Agree	Neither Agree Nor Disagree	Disagree	Disagree	Agree	Agree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Disagree	Agree	Agree	Agree	Agree	Disagree	Agree	Agree
28	Strongly Agree	Strongly Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Agree	Strongly Agree	Agree	Strongly Agree	Neither Agree Nor Disagree	Agree	Neither Agree Nor Disagree	Agree	Agree	Agree	Strongly Agree	Strongly Agree
30	Agree	Agree	Agree	Neither Agree Nor Disagree	Agree	Agree	Neither Agree Nor Disagree	Agree	Agree	Agree	Agree	Neither Agree Nor Disagree	Agree	Agree	Agree	Agree	Neither Agree Nor Disagree	Agree	Agree
31	Disagree	Disagree	Disagree	Disagree	Strongly Disagree	Strongly Disagree	Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Disagree	Disagree	Strongly Disagree	Neither Agree Nor Disagree	Disagree
36	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Agree	Agree	Agree	Neither Agree Nor Disagree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Strongly Agree	Strongly Agree
37	Strongly Disagree	Strongly Disagree	Strongly Disagree	Strongly Disagree	Strongly Disagree	Strongly Disagree	Strongly Disagree	Disagree	Disagree	Disagree	Neither Agree Nor Disagree	Agree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Strongly Disagree	Strongly Disagree	Neither Agree Nor Disagree	Strongly Disagree	Strongly Disagree
38	Agree	Agree	Strongly Agree	Neither Agree Nor Disagree	Agree	Strongly Agree	Strongly Agree	Agree	Agree	Agree	Agree	Disagree	Agree	Agree	Agree	Agree	Disagree	Strongly Agree	Agree
40	Strongly Agree	Strongly Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Neither Agree Nor Disagree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Neither Agree Nor Disagree	Strongly Agree	Strongly Agree
42	Agree	Agree	Agree	Neither Agree Nor Disagree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Agree	Agree	Strongly Agree	Agree	Agree
43	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Disagree
44	Neither Agree Nor Disagree	Disagree	Agree	Disagree	Neither Agree Nor Disagree	Agree	Disagree	Neither Agree Nor Disagree	Agree	Neither Agree Nor Disagree	Agree	Agree	Neither Agree Nor Disagree	Agree	Neither Agree Nor Disagree	Agree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Agree
45	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Strongly Agree	Agree	Strongly Agree	Strongly Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree
49	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree
50	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree
52	Neither Agree Nor Disagree	Agree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Agree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Agree	Neither Agree Nor Disagree	Agree	Agree
53	Agree	Strongly Agree	Strongly Agree	Agree	Strongly Disagree	Agree	Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Strongly Agree	Agree	Strongly Agree	Agree	Agree	Strongly Agree	Strongly Agree
55	Strongly Agree	Disagree	Agree	Agree	Agree	Disagree	Neither Agree Nor Disagree	Agree	Agree	Agree	Agree	Strongly Disagree	Neither Agree Nor Disagree	Neither Agree Nor Disagree	Disagree	Agree	Neither Agree Nor Disagree		Disagree

Final Report v3

3.2 SELF-PERCEPTION QUESTIONNAIRE – Placebo

					• • • • • •														
	1. Did you	2. Did you	3. Do you	4. Did you	5. Did you	6. Did you	7. Are you	8. Did you	9. Did you	10. Did you	11. Did you	12. Did you	13. Did you	14. Did you	15. Did you	16. Did you	17. Did you	18. Would	19. Were
	notice a	notice a	feel less	notice	notice a	notice a	less worried	notice less	notice your	notice	notice an	notice any	notice an	notice less	notice an	experience	notice an	VOU	VOU
	reduction	reduction	vulnerable	feeling less	reduction	reduction	about	frequent	mood was	feeling less	improveme	weight loss	improveme	fatique?	improveme	fewer sleep	improveme	recommen	satisfied
Subject	in the	in the	tohot	sensitive to	in the	in the	night	mood	more	irritable?	nt in your	or your	nt in your	langue	nt in sleep	interruptio	nt in hair	d the	with the
Number	intensity of	frequency	flashes?		intensity of	-			stable?	ini ubiev	overall	clothes			quality?	ns	volume?	product?	product?
Number			nasnes¢	temperatu		frequency	sweats	swings?	stables				energy		qualitye		volumee	producte	producte
	hot	of hot		re	night	of night	interruptin				mood?	fitting	level?			throughou			1
	flashes?	flashes?		changes?	sweats?	sweats?	g your					better?				t the			1
							sleep?									night?			
																			Neither
1	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Agree Nor
	-	-	-	-	-	-	-	-	-	-		-			-	-	-	-	Disagree
3	Aaree	Aaree	Agree	Agree	Agree	Aaree	Aaree	Agree	Agree	Agree	Aaree	Aaree	Agree	Aaree	Agree	Agree	Aaree	Agree	Agree
5	Agree	Agree	Agree	Agree	Agree	Agree	0.00	0	Agree	Agree	0	0.1	-	0	Agree	Agree	0.0	Agree	-
							Neither	Neither			Neither	Neither	Neither	Neither			Neither		Neither
5	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Agree Nor	Agree Nor	Disagree	Disagree	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Disagree	Disagree	Agree Nor	Disagree	Agree Nor
							Disagree	Disagree			Disagree	Disagree	Disagree	Disagree			Disagree		Disagree
	Neither	Characteria and a	Neither	Neither		Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither
9	Agree Nor	Strongly	Agree Nor	Agree Nor	Disagree	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor
	Disagree	Disagree	Disagree	Disagree	-	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree
			Neither									Neither			-		Neither	· · · ·	
10	Agree	Agree	Agree Nor	Agree	Strongly	Agree	Agree	Agree	Agree	Agree	Agree	Agree Nor	Agree	Agree	Strongly	Strongly	Agree Nor	Agree	Strongly
10	Agree	Agree		Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree		Agree	Agree	Agree	Agree		Agree	Agree
			Disagree									Disagree					Disagree		
	Strongly	Strongly	Strongly	Strongly	Strongly	Strongly	Strongly		Strongly	Strongly	Strongly	Neither					Neither	Strongly	Strongly
11	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree Nor	Agree	Agree	Agree	Agree	Agree Nor	Agree	Agree
	Agree	Agree	Agree	Agree	Agree	Agree	Agree		Agree	Agree	Agree	Disagree					Disagree	Ngico	Agree
		Neither					Neither	Neither	Neither	Neither	Neither				Neither	Neither		Neither	Neither
12	Disagree	Agree Nor	Disagree	Disagree	Disagree	Disagree	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Disagree	Disagree	Disagree	Agree Nor	Agree Nor	Disagree	Agree Nor	Agree Nor
	-	Disagree	-	-	-	, in the second s	Disagree	Disagree	Disagree	Disagree	Disagree	-	~	-	Disagree	Disagree	-	Disagree	Disagree
	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither
16	Agree Nor			Agree Nor		Agree Nor						Agree Nor						Agree Nor	Agree Nor
10		Agree Nor	Agree Nor		Agree Nor		Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor		Agree Nor						
	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree
	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither		Neither	1
18	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree	Agree Nor	Agree
	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree		Disagree	1
	Neither	Neither			Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither
20	Agree Nor	Agree Nor	Agree	Agree	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor
	Disagree	Disagree	-	-	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree
	Strongly	Strongly		Strongly	Strongly	Strongly	Strongly	Strongly	Strongly	Strongly	Strongly	Strongly	Strongly	Strongly	Strongly	Strongly	Strongly	Strongly	Strongly
29	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree
	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Neither	Neither
32												Strongly	Strongly	Strongly	Strongly	Strongly	Strongly		
32	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Disagree	Disagree	Agree	Disagree	Disagree	Disagree	Agree Nor	Agree Nor
	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	-	-	-	-	-	-	Disagree	Disagree
	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither	Neither
33	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor
	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree
	Strongly	Strongly		Strongly	Strongly	Strongly			Strongly	Strongly	Strongly	Strongly						Strongly	Strongly
34	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Aaree	Agree	Agree	Aaree						
	Neither	Neither	Neither	Neither		Neither		Neither	Neither	Neither	0.1	Neither	Neither	Neither	Neither	Neither	Neither	Neither	
35	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree	Agree Nor	Agree	Agree Nor	Agree Nor	Agree Nor	Disagree	Agree Nor	Agree Nor	Disagree					
00	Disagree	Disagree	Disagree	Disagree	, .g. 00	Disagree		Disagree	Disagree	Disagree		Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	
	Disugree	Disagree	Disugree	Disagree		Disagree		Disugree		Disagree		Disagree	Disagree		Disagree	Disagree	~	Lisugiee	├──── ┤
	Strongly		Strongly	Strongly		Strongly			Neither					Neither			Neither		
39	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree Nor	Agree	Agree	Agree	Agree	Agree Nor	Agree	Agree	Agree Nor	Agree	Agree
	g								Disagree					Disagree			Disagree		1
41	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree
							Neither	-			-	Neither						Neither	
44	Disagree	Disagree	Disagree	Disagree	Disagree	Disagroo	Agree Nor	Disagree	Disagree	Disagree	Disagree	Agree Nor	Strongly	Strongly	Disagree	Disagree	Disagree	Agree Nor	Disagroo
46	Disugree	Disugree	Disagree	Disagree	Disagree	Disagree		Disagree	Disagree	Disagree	Disagree		Disagree	Disagree	Disagree	Disagree	Disagree		Disagree
							Disagree					Disagree	-	-				Disagree	<u> </u>
	Neither		Neither	Neither		1	1	Neither	1	Neither		1	Neither	1	Neither	1	1	Neither	Neither
47	Agree Nor	Disagree	Agree Nor	Agree Nor	Disagree	Disagree	Disagree	Agree Nor	Disagree	Agree Nor	Disagree	Disagree	Agree Nor	Disagree	Agree Nor	Disagree	Disagree	Agree Nor	Agree Nor
	Disagree		Disagree	Disagree		L	L	Disagree		Disagree			Disagree	L	Disagree			Disagree	Disagree
48	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree	Agree
								Neither	Neither	Neither	Neither		Neither	Neither					
F 1	Strongly	Strongly	Strongly	Strongly	Strongly	Strongly	Strongly					Strongly			Strongly	Strongly	Strongly	Strongly	Strongly
51	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Disagree	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Disagree	Agree Nor	Agree Nor	Disagree	Disagree	Disagree	Disagree	Disagree
		. .		-		<u> </u>	<u> </u>	Disagree	Disagree	Disagree	Disagree		Disagree	Disagree	<u> </u>		<u> </u>		
				Neither				Neither	Neither	Neither	Neither	Neither		Neither					(I
54	Agree	Agree	Agree	Agree Nor	Agree	Agree	Agree	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree Nor	Agree	Agree Nor	Agree	Agree	Disagree	Agree	Agree
			1	Disagree				Disagree	Disagree	Disagree	Disagree	Disagree	1	Disagree	1		1		1

Final Report v3

RECORD RETENTION STATEMENT

All study source documents, and a copy of the signed final report will remain on file with PCR Corp. for a period of at least 3 years, at the end of which time the Sponsor will be contacted for transfer of the files to their own archive or permission obtained to destroy these records. A permanent record of the study will be retained in a readily retrievable form.

ADVERTISING STATEMENT

PCR Corp. submits this report with the understanding that the Sponsor may use the study report for its own purposes. PCR Corp. agrees, not to use the name of the Sponsor or any derivation thereof, in any publication without the prior written consent of the Sponsor.

USE OF PCR CORP., STAFF NAMES, SYMBOLS, WATERMARKS AND LOGOS:

This report may be used by the Sponsor for their own purpose. However, the Sponsor shall not use or authorize any others to use the company name, staff names, symbols, watermarks and logos of PCR Corp. in any advertisements, or any marketing material or allow use of any statement or representation in relation to the study, that is suggestive of an implied endorsement by PCR Corp. of the product or service without a written approval from PCR Corp.